Isis Pharmaceuticals receives first $7.5 million milestone payment from AstraZeneca for ISIS-STAT3

5 November 2014

US pharma company Isis Pharmaceuticals (Nasdaq: ISIS) has earned the first of two milestone payments from Anglo-Swedish drug major AstraZeneca (LSE: AZN) for the advancement of ISIS-STAT3 in patients with advanced cancers.

The two payments come in instalments of $7.5 million, and the second will be awarded to Isis on the initiation of a Phase II study. Isis has completed a clinical study of ISIS-STAT3 in patients with advanced cancers, and results will be presented in an upcoming meeting.

The compound is currently being evaluated in advanced metastatic liver cancer, but AstraZeneca plans to initiate additional clinical studies.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK